On April 2, 2025, leaders from across the life sciences sector gathered at The Westin Palace in Milan for AI for Life Science Excellence — an exclusive event co-hosted by Hyntelo, a leading AI solution provider, and Veeva, a global leader in cloud solutions for the pharmaceutical and life sciences industries.
This collaborative initiative — tailored for the Italian market — offered a unique moment to reflect on how artificial intelligence is already transforming the life sciences value chain, from R&D to patient engagement. The event was held entirely in Italian and attracted decision-makers from pharma, healthcare institutions, and research centers.
The event opened with remarks from Francesca Maggi (Veeva) and Giacomo Filippo Porzio (Hyntelo CEO), who highlighted the importance of their strategic partnership. Hyntelo is currently Veeva’s only AI Partner in Italy, a collaboration that enables the seamless integration of cutting-edge AI solutions within the Veeva ecosystem.
Porzio likened the role of AI to that of electricity — a pervasive force set to influence every corner of the pharmaceutical industry. He shared practical examples of how AI is already enhancing Hyntelo’s internal productivity and being deployed to optimize clinical, medical, and commercial processes across pharma companies.
From content tagging and compliance automation to personalized physician interactions and conversational assistants, the audience was shown how AI can accelerate time-to-insight, support regulatory review, and empower field teams through intelligent planning and reporting.
A standout moment of the event was the expert panel, moderated by Patrizio Armeni from SDA Bocconi. The discussion explored real-world use cases, challenges, and ethical considerations surrounding AI adoption in life sciences.
Key takeaways included:
AI in Clinical Trials:
Dr. Marco Scatigna (IRCCS Monzino) emphasized how AI can drastically improve the design and execution of clinical trials — from protocol creation to patient retention — reducing costs and timelines while increasing success rates.
Operational and Cultural Barriers:
Andrea Pagliai (Gemelli Digital Medicine & Health) underscored that while the technology is ready, it’s the operational models, regulatory frameworks, and change management that need to catch up. Adoption requires not just tools, but a rethinking of healthcare delivery.
AI for Predictive and Preventive Care:
Alessandra Gelera (Assolombarda) highlighted AI’s potential to predict and prevent health events, calling for new organizational models and value-based healthcare systems that reward outcomes, not just procedures.
Strategic and Ethical Considerations:
Joining remotely, Nicoletta Luppi (MSD Italy) stressed AI’s strategic relevance across the pharma value chain — from R&D to personalized engagement — and reminded the audience of the ethical responsibilities that come with it. Data quality, bias mitigation, and human oversight must be core pillars of any AI deployment.
In the closing session, Veeva’s Francesca Maggi gave a live demo of their upcoming AI-powered tools, including voice-controlled CRM interactions and generative AI applications for content review and field activity reporting — all integrated within the Veeva Vault ecosystem and enabled by partners like Hyntelo.
As the event concluded, Giacomo Porzio and Francesca Maggi summed up the main insights that resonated across the afternoon. Here are the five key takeaways:
AI as a Turning Point in Drug Development
Artificial Intelligence is set to dramatically accelerate drug development timelines. The potential economic savings were described as “incredible,” marking a transformative leap in the industry’s efficiency.
The Technology Is Ready – The Challenge Is Organizational
The real question is no longer what AI can do, but how it is implemented. Success hinges on change management, organizational design, and a cultural readiness to embrace AI-driven processes.
AI as Both Strategic and Operational Ally
From R&D planning to marketing and customer engagement, AI is no longer a distant concept. It's already delivering tangible value in the daily operations of pharmaceutical companies.
Measuring Impact Is Essential
The importance of defining KPIs to track adoption and performance was underscored. Any investment in AI must be tied to clear, measurable business outcomes.
AI Is Not Just Hype
AI has passed the hype phase. It’s here, it’s real, and it’s reshaping how the life sciences industry operates.
The Milan event marked more than just a moment of knowledge sharing — it signaled a collective step forward toward a more intelligent, efficient, and patient-centered healthcare system. As Hyntelo and Veeva continue to drive innovation together, the message was clear: the future of life sciences is already here, powered by AI, and it’s up to each organization to harness its full potential.